Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Jul;97(1):26–32. doi: 10.1111/j.1365-2249.1994.tb06574.x

The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

A C Issekutz 1, A Meager 1, I Otterness 1, T B Issekutz 1
PMCID: PMC1534798  PMID: 8033415

Abstract

The mediators involved in leucocyte recruitment to joints during arthritis are not fully defined, but two important proinflammatory cytokines, IL-1 and tumour necrosis factor-alpha (TNF-alpha), are produced in joints in rheumatoid arthritis (RA). We investigated in the rat adjuvant arthritis model whether endogenous IL-1 and TNF-alpha contribute to joint inflammation and polymorphonuclear leucocyte (PMNL) and T lymphocyte infiltration. The migration of 51Cr-labelled rat blood PMNL and 111In-labelled T lymphocytes to the joints of rats with adjuvant arthritis was measured along with plasma protein extravasation, which was quantified using 125I-labelled human albumin. Rats with active arthritis of 5 days' duration received i.p. non-immune serum, polyclonal neutralizing anti-serum to rat TNF-alpha, antiserum to IL-1 alpha and IL-1 beta, or both anti-TNF plus anti-IL-1 for 5 days. Treatment with anti-IL-1 alpha and IL-1 beta did not affect plasma protein extravasation, or PMNL or T lymphocyte accumulation in the joints (i.e. talar joint, hind paws, and tail) despite the fact that this treatment inhibited 80-90% of the PMNL migration into dermal sites injected with IL-1 alpha or IL-1 beta. In contrast, anti-TNF-alpha treatment significantly improved clinical scores, decreased plasma protein extravasation by 60-80%, inhibited PMNL accumulation by 40-50% and decreased T lymphocyte accumulation by 30-50%. Treatment with anti-IL-1, together with anti-TNF-alpha, significantly potentiated the inhibition of T lymphocyte accumulation observed with anti-TNF-alpha alone. These results indicate that endogenous TNF-alpha production may play an important role in the inflammatory changes and leucocyte recruitment in this experimental model of human arthritis, while IL-1 may have a less important role in leucocyte recruitment to these joints.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P., Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315. doi: 10.1002/art.1780330302. [DOI] [PubMed] [Google Scholar]
  2. Breedveld F. C., Trentham D. E. Progress in the understanding of inducible models of chronic arthritis. Rheum Dis Clin North Am. 1987 Dec;13(3):531–544. [PubMed] [Google Scholar]
  3. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  4. Brennan F. M., Maini R. N., Feldmann M. TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992 May;31(5):293–298. doi: 10.1093/rheumatology/31.5.293. [DOI] [PubMed] [Google Scholar]
  5. Bromberg J. S., Chavin K. D., Kunkel S. L. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J Immunol. 1992 Jun 1;148(11):3412–3417. [PubMed] [Google Scholar]
  6. Chensue S. W., Shmyr-Forsch C., Otterness I. G., Kunkel S. L. The beta form is the dominant interleukin 1 released by murine peritoneal macrophages. Biochem Biophys Res Commun. 1989 Apr 14;160(1):404–408. doi: 10.1016/0006-291x(89)91670-7. [DOI] [PubMed] [Google Scholar]
  7. Chu C. Q., Field M., Feldmann M., Maini R. N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Sep;34(9):1125–1132. doi: 10.1002/art.1780340908. [DOI] [PubMed] [Google Scholar]
  8. Daumy G. O., Merenda J. M., McColl A. S., Andrews G. C., Franke A. E., Geoghegan K. F., Otterness I. G. Isolation and characterization of biologically active murine interleukin-1 alpha derived from expression of a synthetic gene in Escherichia coli. Biochim Biophys Acta. 1989 Sep 14;998(1):32–42. doi: 10.1016/0167-4838(89)90115-5. [DOI] [PubMed] [Google Scholar]
  9. Daumy G. O., Wilder C. L., Merenda J. M., McColl A. S., Geoghegan K. F., Otterness I. G. Reduction of biological activity of murine recombinant interleukin-1 beta by selective deamidation at asparagine-149. FEBS Lett. 1991 Jan 14;278(1):98–102. doi: 10.1016/0014-5793(91)80093-i. [DOI] [PubMed] [Google Scholar]
  10. Dinarello C. A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis. 1991 Jun;163(6):1177–1184. doi: 10.1093/infdis/163.6.1177. [DOI] [PubMed] [Google Scholar]
  11. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  12. Firestein G. S. Cytokines in autoimmune diseases. Concepts Immunopathol. 1992;8:129–160. [PubMed] [Google Scholar]
  13. Holt I., Cooper R. G., Denton J., Meager A., Hopkins S. J. Cytokine inter-relationships and their association with disease activity in arthritis. Br J Rheumatol. 1992 Nov;31(11):725–733. doi: 10.1093/rheumatology/31.11.725. [DOI] [PubMed] [Google Scholar]
  14. Hopkins S. J., Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol. 1988 Jul;73(1):88–92. [PMC free article] [PubMed] [Google Scholar]
  15. Issekutz A. C., Issekutz T. B. Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma. J Immunol. 1993 Aug 15;151(4):2105–2115. [PubMed] [Google Scholar]
  16. Issekutz A. C., Issekutz T. B. Quantitation and kinetics of polymorphonuclear leukocyte and lymphocyte accumulation in joints during adjuvant arthritis in the rat. Lab Invest. 1991 May;64(5):656–663. [PubMed] [Google Scholar]
  17. Issekutz A. C., Lopes N. Endotoxin activation of endothelium for polymorphonuclear leucocyte transendothelial migration and modulation by interferon-gamma. Immunology. 1993 Aug;79(4):600–607. [PMC free article] [PubMed] [Google Scholar]
  18. Issekutz A. C., Movat K. W., Movat H. Z. Enhanced vascular permeability and haemorrhage-inducing activity of rabbit C5ades arg: probable role of polymorphonuclear leucocyte lysosomes. Clin Exp Immunol. 1980 Sep;41(3):512–520. [PMC free article] [PubMed] [Google Scholar]
  19. Issekutz A. C. Vascular responses during acute neutrophilic inflammation. Their relationship to in vivo neutrophil emigration. Lab Invest. 1981 Nov;45(5):435–441. [PubMed] [Google Scholar]
  20. Issekutz T. B., Issekutz A. C. T lymphocyte migration to arthritic joints and dermal inflammation in the rat: differing migration patterns and the involvement of VLA-4. Clin Immunol Immunopathol. 1991 Dec;61(3):436–447. doi: 10.1016/s0090-1229(05)80014-5. [DOI] [PubMed] [Google Scholar]
  21. Issekutz T. B., Stoltz J. M., vd Meide P. Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma. J Immunol. 1988 May 1;140(9):2989–2993. [PubMed] [Google Scholar]
  22. Karkar A. M., Koshino Y., Cashman S. J., Dash A. C., Bonnefoy J., Meager A., Rees A. J. Passive immunization against tumour necrosis factor-alpha (TNF-alpha) and IL-1 beta protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol. 1992 Nov;90(2):312–318. doi: 10.1111/j.1365-2249.1992.tb07948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. LeMay L. G., Otterness I. G., Vander A. J., Kluger M. J. In vivo evidence that the rise in plasma IL 6 following injection of a fever-inducing dose of LPS is mediated by IL 1 beta. Cytokine. 1990 May;2(3):199–204. doi: 10.1016/1043-4666(90)90016-m. [DOI] [PubMed] [Google Scholar]
  24. Lonnemann G., Endres S., Van der Meer J. W., Cannon J. G., Koch K. M., Dinarello C. A. Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur J Immunol. 1989 Sep;19(9):1531–1536. doi: 10.1002/eji.1830190903. [DOI] [PubMed] [Google Scholar]
  25. Mahadevan V., Malik S. T., Meager A., Fiers W., Lewis G. P., Hart I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res. 1990 Sep 1;50(17):5537–5542. [PubMed] [Google Scholar]
  26. Mainardi C. L. Biochemical mechanisms of articular destruction. Rheum Dis Clin North Am. 1987 Aug;13(2):215–233. [PubMed] [Google Scholar]
  27. Maini R. N., Brennan F. M., Williams R., Chu C. Q., Cope A. P., Gibbons D., Elliott M., Feldmann M. TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol. 1993 Mar-Apr;11 (Suppl 8):S173–S175. [PubMed] [Google Scholar]
  28. Malyak M., Swaney R. E., Arend W. P. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum. 1993 Jun;36(6):781–789. doi: 10.1002/art.1780360607. [DOI] [PubMed] [Google Scholar]
  29. Oppenheim J. J., Zachariae C. O., Mukaida N., Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617–648. doi: 10.1146/annurev.iy.09.040191.003153. [DOI] [PubMed] [Google Scholar]
  30. Piguet P. F., Grau G. E., Vesin C., Loetscher H., Gentz R., Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 1992 Dec;77(4):510–514. [PMC free article] [PubMed] [Google Scholar]
  31. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol Rev. 1990 Apr;70(2):427–451. doi: 10.1152/physrev.1990.70.2.427. [DOI] [PubMed] [Google Scholar]
  32. Smith-Oliver T., Noel L. S., Stimpson S. S., Yarnall D. P., Connolly K. M. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine. 1993 Jul;5(4):298–304. doi: 10.1016/1043-4666(93)90060-i. [DOI] [PubMed] [Google Scholar]
  33. Taurog J. D., Argentieri D. C., McReynolds R. A. Adjuvant arthritis. Methods Enzymol. 1988;162:339–355. doi: 10.1016/0076-6879(88)62089-1. [DOI] [PubMed] [Google Scholar]
  34. Thorbecke G. J., Shah R., Leu C. H., Kuruvilla A. P., Hardison A. M., Palladino M. A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7375–7379. doi: 10.1073/pnas.89.16.7375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wankowicz Z., Megyeri P., Issekutz A. Synergy between tumour necrosis factor alpha and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation. J Leukoc Biol. 1988 Apr;43(4):349–356. doi: 10.1002/jlb.43.4.349. [DOI] [PubMed] [Google Scholar]
  36. Wedmore C. V., Williams T. J. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature. 1981 Feb 19;289(5799):646–650. doi: 10.1038/289646a0. [DOI] [PubMed] [Google Scholar]
  37. Wilder R. L., Case J. P., Crofford L. J., Kumkumian G. K., Lafyatis R., Remmers E. F., Sano H., Sternberg E. M., Yocum D. E. Endothelial cells and the pathogenesis of rheumatoid arthritis in humans and streptococcal cell wall arthritis in Lewis rats. J Cell Biochem. 1991 Feb;45(2):162–166. doi: 10.1002/jcb.240450207. [DOI] [PubMed] [Google Scholar]
  38. Williams J. H., Jr, Moser K. M., Ulich T., Cairo M. S. Harvesting the noncirculating pool of polymorphonuclear leukocytes in rats by hetastarch exchange transfusion (HET): yield and functional assessment. J Leukoc Biol. 1987 Nov;42(5):455–462. doi: 10.1002/jlb.42.5.455. [DOI] [PubMed] [Google Scholar]
  39. Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. van de Loo F. A., Arntz O. J., Otterness I. G., van den Berg W. B. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol. 1992 Mar;19(3):348–356. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES